Insulet (PODD) just paired a strong third quarter earnings release with higher full year revenue guidance and a new US$1b share repurchase plan, giving investors several fresh data points to assess.
Recent trading tells a more mixed story. Insulet’s share price has risen around 9.5% over the past month and is slightly higher over 90 days, yet the stock is still down sharply on a year to date basis, and the 1 year total shareholder return has fallen more than 50%. This suggests the latest guidance upgrade and US$1b buyback are being weighed against a much weaker longer term experience for holders.
Compare Insulet’s sharp 1 year share price slide with companies that have held up better by scanning our curated list of 30 resilient stocks with low risk scores.
After a sharp 1 year slide and a recent bounce on stronger guidance and a US$1b buyback, Insulet now sits in an awkward middle ground. Does it make more sense to lean in here, or to wait for a cleaner entry based on valuation?
Most Popular Narrative: 17% Undervalued
On the analyst consensus Narrative on Simply Wall St, Insulet screens as undervalued, with a fair value of $178.35 against a last close of $148.06. That gap reflects a detailed set of revenue and earnings forecasts run through a 7.68% discount rate.
The current valuation implies the market is not fully crediting Insulet for the underpenetrated AID opportunity, its recurring high margin pod model, and the planned Omnipod algorithm and product upgrades.
A robust product and algorithm roadmap, including recent Omnipod 5 enhancements such as a 100 mg/dL glucose target and Libre 3 Plus integration, the Omnipod 6 pivotal data showing higher time in range and fewer boluses, and a fully closed loop type 2 system in pivotal trials for a planned 2028 launch, creates multiple future upgrade cycles that can support higher revenue and potentially higher net margins as users migrate to newer systems.
See why 24 investors see Insulet as 17% undervalued.
Result: Fair Value of $178.35 (UNDERVALUED)
Still, Insulet’s story can change quickly if type 2 retention remains weak, or if recall and litigation issues weigh on clinician confidence and new customer starts.
Find out about the key risks to this Insulet narrative.
Next Steps
Seeing mixed signals on Insulet and feeling unsure which side of the story matters more right now. Act quickly by weighing the full picture of potential upsides through the 5 key rewards.
Looking for more investment ideas beyond Insulet?
You do not need to stop with Insulet. Put a shortlist together quickly so you can compare opportunities side by side instead of reacting to headlines.
- Target consistency by reviewing companies that appear in our list of solid balance sheet and fundamentals (24 results) and keep financial resilience front and center in your process.
- Hunt for mispriced opportunities by scanning the 35 high quality undervalued stocks and see which businesses the numbers suggest may trade below their fundamentals.
- Build your income watchlist by checking the 5 dividend fortresses and filter for payouts that meet your return and risk comfort zone.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com